XML 24 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Original and Further Restatement of the Consolidated Financial Statements (Tables)
9 Months Ended
Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]  
Effects of Further Adjustments to Previously Filed Consolidated Income Statements

The tables below show the effects of the Further Restatement for the fiscal quarter ended September 30, 2013 and the nine months ended September 30, 2013. The tax effect of the adjustments is estimated based on the Company’s estimated tax rate.

 

 

    Three Months Ended September 30, 2013  
          Further Restatement Adjustments by Category        
(U.S. Dollars, in thousands)   Originally
Reported in
2013

Form 10-Q
    Co-Pay and
Self-Pay
Revenue
    Bad Debt
Timing
    Accounts
Receivable
Reserve
    Intercompany
Profit
    Inventory     Other     Total Further
Restatement
Adjustments
    Restated  

Net sales

  $ 92,738      $ (1,191 )    $ —       $ 240      $ —       $ —       $ 19      $ (932 )    $ 91,806   

Cost of sales

    23,920        —         —         —         770        1,320        (946 )      1,144        25,064   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

  68,818      (1,191 )    —       240      (770 )    (1,320 )    965      (2,076 )    66,742   

Operating expenses

Sales and marketing

  42,382      (1,191 )    —       14      —       —       (2,129 )    (3,306 )    39,076   

General and administrative

  13,202      —       —       —       —       —       (269 )    (269 )    12,933   

Research and development

  6,361      —       —       —       —       —       —       —       6,361   

Amortization of intangible assets

  616      —       —       —       —       —       —       —       616   

Costs related to the accounting review and restatement

  2,664      —       —       —       —       —       —       —       2,664   

Impairment of goodwill

  19,193      —       —       —       —       —       —       —       19,193   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
  84,418      (1,191 )    —       14      —       —       (2,398 )    (3,575 )    80,843   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating (loss) income

  (15,600 )    —       —       226      (770 )    (1,320 )    3,363      1,499      (14,101 ) 

Other income and (expense)

  (2,036 )    —       —       —       —       —       16      16      (2,020 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss before income taxes

  (17,636 )    —       —       226      (770 )    (1,320 )    3,379      1,515      (16,121 ) 

Income tax expense

  (448 )    —       —       (79 )    (270 )    462      (588 )    65      (383 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss from continuing operations

$ (18,084 )  $ —     $ —     $ 147    $ (500 )  $ (850 )  $ 2,791    $ 1,580    $ (16,504 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

    Nine Months Ended September 30, 2013  
          Further Restatement Adjustments by Category        
(U.S. Dollars, in thousands)   Originally
Reported in
2013
Form 10-Q
    Co-Pay and
Self-Pay
Revenue
    Bad Debt
Timing
    Accounts
Receivable

Reserve
    Intercompany
Profit
    Inventory     Other     Total Further
Restatement
Adjustments
    Restated  

Net sales

  $ 294,391      $ (2,980 )    $ —       $ 364     $ —       $ —        $ (50 )    $ (2,666 )    $ 291,725   

Cost of sales

    69,783        —         —         —         1,012        3,399        (1,405 )      3,006        72,789   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

  224,608      (2,980 )    —       364     (1,012 )    (3,399 )    1,355    $ (5,672 )    218,936   

Operating expenses

Sales and marketing

  132,346      (2,980 )    1,455      54     —       —        (1,416 )    (2,887 )    129,459   

General and administrative

  46,736      —       —       —       —       —        (381 )    (381 )    46,355   

Research and development

  20,653      —       —       —       —       —        —        —       20,653   

Amortization of intangible assets

  1,725      —       —       —       —       —        —        —       1,725   

Costs related to accounting review and restatement

  2,664      —       —       —       —       —        —        —       2,664   

Impairment of goodwill

  19,193      —       —       —       —       —        —        —       19,193   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
  223,317      (2,980 )    1,455      54     —       —        (1,797 )    (3,268 )    220,049   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

  1,291      —       (1,455 )    310     (1,012 )    (3,399 )    3,152      (2,404 )    (1,113 ) 

Other income and (expense)

  491      —       —       —       —       —        49      49      540   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss before income taxes

  1,782      —       (1,455 )    310     (1,012 )    (3,399 )    3,201      (2,355 )    (573 ) 

Income tax expense

  (8,126 )    —       509      (109 )   354      1,190      (1,811 )    133      (7,993 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss from continuing operations

$ (6,344 )  $  —      $ (964 )  $ 201    $ (658 )  $ (2,209 )  $ 1,390    $ (2,222 )  $ (8,566 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

Effects of Further Restatement on Consolidated Balance Sheet

The effects of the Further Restatement on the condensed consolidated balance sheet as of December 31, 2013 are as follows:

 

     As of December 31, 2013  

(Unaudited, U.S. Dollars, in thousands, except share data)

   Originally
Reported in
2013
Form 10-K
     Further
Restatement
Adjustments
     Restated  

Assets

        

Current assets:

        

Cash and cash equivalents

   $ 30,486       $ (1,562 )     $ 28,924   

Restricted cash

     23,761         —           23,761   

Trade accounts receivable, less allowances of $9,111 at December 31, 2013

     75,567         (4,756 )       70,811   

Inventories

     90,577         (17,899 )       72,678   

Deferred income taxes

     33,947         6,052         39,999   

Prepaid expenses and other current assets

     25,906         3,027         28,933   
  

 

 

    

 

 

    

 

 

 

Total current assets

  280,244      (15,138 )    265,106   

Property, plant and equipment, net

  54,606      (234 )    54,372   

Patents and other intangible assets, net

  9,046      —        9,046   

Goodwill

  53,565      —        53,565   

Deferred income taxes

  18,336      4,058      22,394   

Other long-term assets

  7,385      107      7,492   
  

 

 

    

 

 

    

 

 

 

Total assets

$ 423,182    $ (11,207 )  $ 411,975   
  

 

 

    

 

 

    

 

 

 

Liabilities and shareholders’ equity

Current liabilities:

Trade accounts payable

$ 20,674    $ —      $ 20,674   

Other current liabilities

  46,146      3,530      49,676   
  

 

 

    

 

 

    

 

 

 

Total current liabilities

  66,820      3,530      70,350   

Long-term debt

  20,000      —        20,000   

Deferred income taxes

  13,132      (106 )    13,026   

Other long-term liabilities

  12,736      —        12,736   
  

 

 

    

 

 

    

 

 

 

Total liabilities

  112,688      3,424      116,112   

Contingencies (Note 16)

Shareholders’ equity:

Common shares $0.10 par value; 50,000,000 shares authorized; 18,102,335 issued and outstanding as of December 31, 2013

  1,810      —        1,810   

Additional paid-in capital

  216,653      —        216,653   

Retained earnings

  89,332      (15,435 )    73,897   

Accumulated other comprehensive income

  2,699      804      3,503   
  

 

 

    

 

 

    

 

 

 

Total shareholders’ equity

  310,494      (14,631 )    295,863   
  

 

 

    

 

 

    

 

 

 

Total liabilities and shareholders’ equity

$ 423,182    $ (11,207 )  $ 411,975   
  

 

 

    

 

 

    

 

 

 

Effects of Further Restatements of Consolidated Statement of Operations and Comprehensive Loss

The effects of the Further Restatement on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2013 are as follows:

 

     Three Months Ended September 30, 2013  

(Unaudited, U.S. Dollars, in thousands, except share and per share data)

   Originally
Reported in 2013

Form 10-Q
     Further
Restatement
Adjustments
     Restated  

Product sales

   $ 81,061       $ (1,024 )     $ 80,037   

Marketing service fees

     11,677         92         11,769   
  

 

 

    

 

 

    

 

 

 

Net sales

  92,738      (932 )    91,806   

Cost of sales

  23,920      1,144      25,064   
  

 

 

    

 

 

    

 

 

 

Gross profit

  68,818      (2,076 )    66,742   

Operating expenses

Sales and marketing

  42,382      (3,306 )    39,076   

General and administrative

  13,202      (269 )    12,933   

Research and development

  6,361      —       6,361   

Amortization of intangible assets

  616      —       616   

Costs related to the accounting review and restatement

  2,664      —       2,664   

Impairment of goodwill

  19,193      —       19,193   
  

 

 

    

 

 

    

 

 

 
  84,418      (3,575 )    80,843   
  

 

 

    

 

 

    

 

 

 

Operating loss

  (15,600 )    1,499      (14,101 ) 

Other income and expense

Interest expense, net

  (555 )    16     (539 ) 

Other expense

  (1,481 )    —       (1,481 ) 
  

 

 

    

 

 

    

 

 

 
  (2,036 )    16     (2,020 ) 
  

 

 

    

 

 

    

 

 

 

Loss before income taxes

  (17,636 )    1,515      (16,121 ) 

Income tax expense

  (448 )    65      (383 ) 
  

 

 

    

 

 

    

 

 

 

Net loss from continuing operations

  (18,084 )    1,580      (16,504 ) 
  

 

 

    

 

 

    

 

 

 

Discontinued operations (Note 15)

Loss from discontinued operations

  (3,041 )    666     (2,375 ) 

Income tax benefit

  1,303      (1,260 )    43   
  

 

 

    

 

 

    

 

 

 

Net loss from discontinued operations, net of tax

  (1,738 )    (594 )    (2,332 ) 
  

 

 

    

 

 

    

 

 

 

Net loss

$ (19,822 )  $ 986    $ (18,836 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-basic:

Net loss from continuing operations, net of tax

$ (1.00 )  $ 0.09    $ (0.91 ) 

Net loss from discontinued operations, net of tax

  (0.10 )    (0.03 )    (0.13 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-basic

$ (1.10 )  $ 0.06    $ (1.04 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-diluted:

Net loss from continuing operations, net of tax

$ (1.00 )  $ 0.09    $ (0.91 ) 

Net loss from discontinued operations, net of tax

  (0.10 )    (0.03 )    (0.13 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-diluted

$ (1.10 )  $ 0.06    $ (1.04 ) 
  

 

 

    

 

 

    

 

 

 

Weighted average number of common shares:

Basic

  18,142,935      —       18,142,935   

Diluted

  18,142,935      —       18,142,935   

Comprehensive loss

$ (16,064 )  $ 1,017    $ (15,047 ) 
  

 

 

    

 

 

    

 

 

 

 

     Nine Months Ended September 30, 2013  

(Unaudited, U.S. Dollars, in thousands, except share and per share data)

   Originally
Reported in 2013
Form 10-Q
     Further
Restatement
Adjustments
     Restated  

Product sales

   $ 259,030       $ (2,823 )     $ 256,207   

Marketing service fees

     35,361         157         35,518   
  

 

 

    

 

 

    

 

 

 

Net sales

  294,391      (2,666 )    291,725   

Cost of sales

  69,783      3,006      72,789   
  

 

 

    

 

 

    

 

 

 

Gross profit

  224,608      (5,672 )    218,936   

Operating expenses

Sales and marketing

  132,346      (2,887 )    129,459   

General and administrative

  46,736      (381 )    46,355   

Research and development

  20,653      —        20,653   

Amortization of intangible assets

  1,725      —        1,725   

Costs related to the accounting review and restatement

  2,664     —        2,664   

Impairment of goodwill

  19,193      —        19,193   
  

 

 

    

 

 

    

 

 

 
  223,317      (3,268 )    220,049   
  

 

 

    

 

 

    

 

 

 

Operating income (loss)

  1,291      (2,404 )    (1,113 ) 

Other income and expense

Interest expense, net

  (1,585 )    49     (1,536 ) 

Other income

  2,076      —        2,076   
  

 

 

    

 

 

    

 

 

 
  491      49     540   
  

 

 

    

 

 

    

 

 

 

Income (loss) before income taxes

  1,782      (2,355 )    (573 ) 

Income tax expense

  (8,126 )    133      (7,993 ) 
  

 

 

    

 

 

    

 

 

 

Net loss from continuing operations

  (6,344 )    (2,222 )    (8,566 ) 
  

 

 

    

 

 

    

 

 

 

Discontinued operations (Note 15)

Loss from discontinued operations

  (16,629 )    2,202     (14,427 ) 

Income tax benefit

  5,334      (741 )    4,593   
  

 

 

    

 

 

    

 

 

 

Net loss from discontinued operations

  (11,295 )    1,461      (9,834 ) 
  

 

 

    

 

 

    

 

 

 

Net loss

$ (17,639 )  $ (761 )  $ (18,400 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-basic:

Net loss from continuing operations

$ (0.34 )  $ (0.11 )  $ (0.45 ) 

Net loss from discontinued operations

  (0.60 )    0.08      (0.52 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-basic

$ (0.94 )  $ (0.03 )  $ (0.97 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-diluted:

Net loss from continuing operations

$ (0.34 )  $ (0.11 )  $ (0.45 ) 

Net loss from discontinued operations

  (0.60 )    0.08      (0.52 ) 
  

 

 

    

 

 

    

 

 

 

Net loss per common share-diluted

$ (0.94 )  $ (0.03 )  $ (0.97 ) 
  

 

 

    

 

 

    

 

 

 

Weighted average number of common shares:

Basic

  18,897,887      —        18,897,887   

Diluted

  18,897,887      —        18,897,887   

Comprehensive loss

$ (17,426 )  $ (671 )  $ (18,097 ) 
  

 

 

    

 

 

    

 

 

Effects of Restatements of Condensed Consolidated Statement of Cash Flows

The effects of the Further Restatement on the condensed consolidated statement of cash flows for the nine months ended September 30, 2013 are as follows:

 

     Nine Months Ended September 30, 2013  

(Unaudited, U.S. Dollars, in thousands)

   Originally
Reported in
2013
Form 10-Q
     Further
Restatement
Adjustments
     Restated  

Cash flows from operating activities:

        

Net loss

   $ (17,639 )     $ (761 )     $ (18,400 ) 

Adjustments to reconcile net loss to net cash provided by operating activities:

        

Depreciation and amortization

     15,459         126        15,585   

Amortization of debt costs

     540         —          540   

Amortization of exclusivity agreements

     —           1,069         1,069   

Provision for doubtful accounts

     4,225         (1,471 )       2,754   

Deferred income taxes

     (223 )       —           (223 ) 

Share-based compensation

     4,714         —           4,714   

Impairment of goodwill

     19,193         —           19,193   

Excess income tax benefit on employee stock-based awards

     (82 )       —           (82 ) 

Other

     (520 )       (645 )       (1,165 ) 

Change in operating assets and liabilities:

        

Trade accounts receivable

     27,758         2,616         30,374   

Inventories

     (11,596 )       2,819         (8,777 ) 

Prepaid expenses and other current assets

     5,541         864         6,405   

Trade accounts payable

     (8,028 )       —           (8,028 ) 

Other current liabilities

     13,040         (3,555 )       9,485   

Long-term assets

     482         (1,907 )       (1,425 ) 

Long-term liabilities

     (912 )       796        (116 ) 
  

 

 

    

 

 

    

 

 

 

Net cash provided by operating activities

  51,952      (49 )    51,903   

Cash flows from investing activities:

Capital expenditures for property, plant and equipment

  (19,427 )    —        (19,427 ) 

Capital expenditures for intangible assets

  (4,525 )    —        (4,525 ) 

Purchase of other investments

  —        (1,232 )    (1,232 ) 
  

 

 

    

 

 

    

 

 

 

Net cash used in investing activities

  (23,952 )    (1,232 )    (25,184 ) 

Cash flows from financing activities:

Net proceeds from issuance of common shares

  3,431      —        3,431   

(Repayment of) proceeds from bank borrowings, net

  (16 )    —        (16 ) 

Changes in restricted cash

  (1,371 )    —        (1,371 ) 

Repurchase of treasury shares

  (39,494 )    —        (39,494 ) 

Excess income tax benefit on employee stock-based awards

  82      —        82   
  

 

 

    

 

 

    

 

 

 

Net cash used in financing activities

  (37,368 )    —        (37,368 ) 

Effect of exchange rate changes on cash

  532      79     611   
  

 

 

    

 

 

    

 

 

 

Net decrease in cash and cash equivalents

  (8,836 )    (1,202 )    (10,038 ) 

Cash and cash equivalents at the beginning of the period

  31,055      (288 )    30,767   
  

 

 

    

 

 

    

 

 

 

Cash and cash equivalents at the end of the period

$ 22,219      (1,490 )  $ 20,729